Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group.

Fabian Trillsch Sven Mahner Bastian Czogalla Miriam Rottmann Radoslav Chekerov Elena Ioana Braicu Gülten Oskay-Öczelik Pauline Wimberger Rolf Richter Jalid Sehouli

Published in: Journal of gynecologic oncology (2021)

Prognostic significance of SPR versus PPR could be elucidated for patients receiving chemotherapy only. In contrast to bevacizumab, the multi-kinase inhibitor sorafenib exhibits profound therapeutic efficacy in PPR patients indicating potential to overcome this negative prognostic impact.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
magnetic resonance
peritoneal dialysis
prognostic factors
intellectual disability
squamous cell carcinoma
computed tomography
locally advanced
climate change
magnetic resonance imaging
patient reported outcomes
human health